What is the real pharmacological rationale for beta-receptor blocking agents?
The intake of beta-receptor blocking agents may result in an improvement in the quality of life by reducing the frequency of angina pectoris attacks. The mode of action is a decrease of MVO2, mostly achieved by a reduction of the heart rate of about 20% during conditions of stress. The minimal oral dosages necessary to achieve this effect have not yet been well defined for the different beta-receptor blocking drugs available. Distinctly lower dosages may be sufficient. Considering these facts, the controversial points of view on the different properties of beta-receptor blocking agents should be re-examined.
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D015784:Betaxolol; D003327:Coronary Disease / Q000188:drug therapy*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D009200:Myocardial Contraction / Q000187:drug effects; D009203:Myocardial Infarction / Q000188:drug therapy; D009206:Myocardium / Q000378:metabolism; D010101:Oxygen Consumption / Q000187:drug effects; D010394:Penbutolol / Q000627:therapeutic use; D005082:Physical Exertion; D011412:Propanolamines / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; D010394:Penbutolol; D011433:Propranolol; D015784:Betaxolol